Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

97.63 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
The company reported in-line sales for the fourth quarter, but shares soared by double digits. 
Via Investor's Business Daily
Opportunities For Investors Beyond AI And Nvidia – Biotech Breaks Out, New GDP Data Shows Inflation Pressure
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
ETF Theme: Range-Bound
Here is the fund for the emerging markets, which is not only range-bound but seems to be following a regular time pattern. 
Via Talk Markets
Topics ETFs
Healthcare Stocks Are Looking Better But What About Biotech?
Large cap biopharmacuiticals remain a core holding for growth and value despite political cross-currents on drug pricing. 
Via Talk Markets
Favoring IWM, XBI, And KRE
It's time to employ ratios. Just like I utilize sector ratios such as XLF to XLU, XLY to XLP, or SPY to TLT, this is the time to look at IWM in comparison to the SPY. 
Via Talk Markets
Sunday ETF Review, Feb. 4, 2024
Examining my 
Via Talk Markets
Topics ETFs
Biotech And Medtech Portfolio Notes On A Fed Day
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23% 
Via Talk Markets
Topics Economy
Exposures Interest Rates
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains 
Via InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
Biotech Playbook: Small Caps Show Momentum Peaking During
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. 
Via Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2023 in Review: Key Stock Trends and Sector Shifts Unveiled
Investors would be smart to pay attention to these stock trends, many of which are taking hold as the New Year begins. 
Via InvestorPlace
Satori Fund's Dan Niles Names Amazon, Meta Top Stocks To Own In 2024
Satori Fund founder and portfolio manager Dan Niles is out with his top stock picks for 2024 and two Magnificent 7 names are at the top of the list. 
Via Benzinga
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky. 
Via The Motley Fool
3 Thematic Growth ETFs to Load Up on Right Now
These three thematic ETFs could be potent growth vehicles in years to come. 
Via The Motley Fool
Topics ETFs
Small Caps Are On A Tear Including Speculative Biotechs
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. 
Via Talk Markets
US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday?
It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
Can Small Cap Biotech Stocks Continue To Run? Let’s Take A Look
Over the past 4 weeks, we have seen a nice run in small-cap, speculative biotech stocks. This coincided with the pause in interest rates and expectations of the seasonal year-end rally. 
Via Talk Markets
Fed Rate Cut Speculations Rattle Stocks, Commodities Slide, Bitcoin Shines: What's Driving Markets Monday?
Stocks opened the first week of December with significant losses, driven by some emerging concerns of exaggerated rate cut speculations within the trading community. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
Kicking off the new month, Wall Street continued its strong November momentum, with major U.S. stocks rallying on Friday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
S&P 500, Nasdaq Slip As Tech Underperforms, Oil Reacts to OPEC+: What's Driving Markets Thursday?
Thursday’s trading session on Wall Street presents a mixed picture, characterized by notable fluctuations in major indices. While tech-heavy benchmarks like the S&P 500 and the Nasdaq 100 are... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Drift Higher On Stronger GDP Data, Oil Rebounds As OPEC+ Mulls Cuts: What's Driving Markets Wednesday?
Stocks are experiencing their 16th green session out of the 20 so far in November, with the S&P 500 index reaching its highest level since early August, and the Nasdaq 100 just 4.4% below its all-time... 
Via Benzinga
US Stocks Rebound As Treasury Yields, Dollar Fall On Dovish Fed Remarks, Gold Hits $2,040: What's Driving Markets Tuesday?
U.S. stocks experienced a welcome resurgence on Tuesday, buoyed by the latest comments from Federal Reserve officials. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
3 Biotech Stocks That Could Boom or Bust by 2025
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday. 
Via InvestorPlace
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.